NasdaqGS - Nasdaq Real Time Price
USD
BioNTech SE (BNTX)
102.08
-9.33
(-8.37%)
At close: August 28 at 4:00:01 PM EDT
102.50
+0.43
(+0.42%)
Pre-Market: 8:32:54 AM EDT
Trade BNTX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for BNTX
What's happening with BNTX?
Powered by Yahoo ScoutBioNTech (BNTX) is navigating a transformative period marked by mixed stock performance and ambitious oncology pipeline developments. Recent insights reveal the company's potential undervaluation and strategic shifts, particularly in cancer treatments, as it seeks to establish itself beyond its COVID-19 vaccine legacy.
Powered by Yahoo Scout
- Previous Close
111.40 - Open
102.26 - Bid 102.17 x 100
- Ask 126.84 x 200
- Day's Range
98.84 - 105.23 - 52 Week Range
79.52 - 124.00 - Volume
3,072,555 - Avg. Volume
1,206,825 - Market Cap (intraday)
25.642B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-7.82 - Earnings Date Nov 3, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 2, 2022
- 1y Target Est
120.24
Recent News
View More
Performance Overview
Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
BNTX
7.13%
MSCI WORLD (^990100-USD-STRD)
12.50%
1-Year Return
BNTX
2.07%
MSCI WORLD (^990100-USD-STRD)
0.00%
3-Year Return
BNTX
18.39%
MSCI WORLD (^990100-USD-STRD)
66.92%
5-Year Return
BNTX
70.02%
MSCI WORLD (^990100-USD-STRD)
58.66%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/27/2026
-
Market Cap
27.98B
-
Enterprise Value
11.13B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
8.93
-
Price/Book (mrq)
1.35
-
Enterprise Value/Revenue
3.60
-
Enterprise Value/EBITDA
32.70
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-63.64%
-
Return on Assets (ttm)
-5.41%
-
Return on Equity (ttm)
-9.30%
-
Revenue (ttm)
2.65B
-
Net Income Avi to Common (ttm)
-1.69B
-
Diluted EPS (ttm)
-7.82
Balance Sheet and Cash Flow
-
Total Cash (mrq)
13.46B
-
Total Debt/Equity (mrq)
1.78%
-
Levered Free Cash Flow (ttm)
-249.56M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
BioNTech Earnings: Guidance Cut but Late-Stage Pipeline Stays on Track
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
BioNTech Earnings: Guidance Cut but Late-Stage Pipeline Stays on Track
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target
